EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study

Maiju Savolainen iD, Merja Soilu-Hänninen, Henriikka Nurmi, Matias Viitala, Pentti Tienari, Sari Atula, Sini M Laakso

European Journal of Neurology · 2026-05 · 33 (5)

DOI: 10.1111/ene.70625 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Neurology, online erschienen am 16.05.2026. Verfasst von Maiju Savolainen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neurocenter, Helsinki University Hospital, and Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Rituximab, Multiple Sclerosis, Relapsing-Remitting, Antibodies, Monoclonal, Humanized, Immunologic Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Helsinki University Hospital, Turku University Hospital, Turun Yliopistollinen Keskussairaala.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

B‐cell–depleting anti‐CD20 therapies are among the most effective disease‐modifying treatments for relapsing–remitting multiple sclerosis (RRMS). Rituximab (RTX) is widely used off‐label, while ocrelizumab (OCR) is approved for RRMS; yet comparative real‐world evidence between the two remains limited.

Methods

We conducted a retrospective registry‐based cohort study using the Finnish MS Registry, including adult RRMS patients treated with RTX or OCR between 2018 and 2024 at two university hospitals. Propensity score matching (1:1) was applied to balance baseline characteristics. Primary outcomes were annualized relapse rate (ARR) during follow‐up and relapse‐free survival. Secondary outcomes included MRI activity, disability progression, adverse events, and longitudinal plasma immunoglobulin G (IgG) levels.

Results

Of 636 screened patients, 191 met inclusion criteria and 112 patients (56 RTX, 56 OCR) were included after matching. Median follow‐up was 3.1 years for RTX and 2.6 years for OCR. ARR was low and similar in both groups (mean 0.03), and relapse‐free survival did not differ (log‐rank p = 0.95; HR 0.95, 95% CI 0.21–4.33). MRI activity remained largely stable, with no significant differences in T2 lesion changes. Adverse events were infrequent and mild. IgG declined modestly in both groups (mean−13%), with values below the reference range in 4.5% of patients and no association with infections. No disease reactivation was observed among patients switching from OCR to RTX.

Conclusions

In this population‐based Finnish real‐world study, RTX and OCR demonstrated comparable effectiveness and safety in RRMS, supporting RTX as a rational alternative to OCR in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabMultiple Sclerosis, Relapsing-RemittingAntibodies, Monoclonal, HumanizedImmunologic FactorsHumansFemaleFinlandAdultMaleRetrospective StudiesMiddle AgedRegistriesCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

anti‐CD20multiple sclerosisocrelizumabreal‐world evidencerituximab

Substanzen

RituximabAntibodies, Monoclonal, HumanizedocrelizumabImmunologic Factors

Autor:innen und Institutionen

  • Neurocenter, Helsinki University Hospital, and Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland.
  • Neurocenter, Turku University Hospital and Division of Clinical Neurosciences, University of Turku, Turku, Finland.
  • StellarQ Ltd, Turku, Finland.
  • Aastat Ltd, Turku, Finland.

ORCID-Profile: Maiju Savolainen

Förderung

  • Helsinki University Hospital
  • Turku University Hospital
  • Turun Yliopistollinen Keskussairaala

Zitieren

APA

Savolainen, M., Soilu-Hänninen, M., Nurmi, H., Viitala, M., Tienari, P., Atula, S., & Laakso, S. M. (2026). Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study. European Journal of Neurology, 33(5). https://doi.org/10.1111/ene.70625

Vancouver

Savolainen M, Soilu-Hänninen M, Nurmi H, Viitala M, Tienari P, Atula S, et al. Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study. European Journal of Neurology. 2026;33(5). doi:10.1111/ene.70625

BibTeX
@article{Savolainen2026,
  author = {Savolainen, Maiju and Soilu-Hänninen, Merja and Nurmi, Henriikka and Viitala, Matias and Tienari, Pentti and Atula, Sari and Laakso, Sini M},
  title = {Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {5},
  doi = {10.1111/ene.70625}
}
Kostenlos starten →